Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several neurotransmitter receptors activate signaling pathways that alter processing of the amyloid precursor protein (APP) into β-amyloid (Aβ). Serotonin signaling through a subset of serotonin receptors suppresses Aβ generation. We proposed that escitalopram, the most specific selective serotonin reuptake inhibitor (SSRI) that inhibits the serotonin transporter SERT, would suppress Aβ levels in mice. OBJECTIVES: We hypothesized that acute treatment with escitalopram would reduce Aβ generation, which would be reflected chronically with a significant reduction in Aβ plaque load. METHODS: We performed in vivo microdialysis and in vivo 2-photon imaging to assess changes in brain interstitial fluid (ISF) Aβ and Aβ plaque size over time, respectively, in the APP/presenilin 1 mouse model of Alzheimer disease treated with vehicle or escitalopram. We also chronically treated mice with escitalopram to determine the effect on plaques histologically. RESULTS: Escitalopram acutely reduced ISF Aβ by 25% by increasing α-secretase cleavage of APP. Chronic administration of escitalopram significantly reduced plaque load by 28% and 34% at 2.5 and 5 mg/d, respectively. Escitalopram at 5 mg/kg did not remove existing plaques, but completely arrested individual plaque growth over time. CONCLUSIONS: Escitalopram significantly reduced Aβ in mice, similar to previous findings in humans treated with acute dosing of an SSRI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Neuronal activity regulates the regional vulnerability to amyloid-β deposition
Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., Lee, J.-M., & Holtzman, D. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2801 · Cited by 880
Self-citationCirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660
Self-citationDepression as a Risk Factor for Alzheimer Disease: The MIRAGE Study
Green, R. C., Cupples, L. A., Kurz, A., Auerbach, S., Go, R., Sadovnick, D., Duara, R., Kukull, W. A., Chui, H., Edeki, T., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.5.753 · Cited by 551
Kinetic theory of fibrillogenesis of amyloid β-protein
Lomakin, A., Teplow, D. B., Kirschner, D. A., & Benedek, G. B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.7942 · Cited by 529
Aβ40 Inhibits Amyloid Deposition In Vivo
Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D. W., Golde, T., & McGowan, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4849-06.2007 · Cited by 415
Klunk, W. E., Bacskai, B. J., Mathis, C. A., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Debnath, M. L., Holt, D. P., Wang, Y., & Hyman, B. T. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.9.797 · Cited by 412
Cited by
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Sheline, Y. I., Snider, B. J., Beer, J. C., Seok, D., Fagan, A. M., Suckow, R. F., Lee, J.-M., Waligorska, T., Korecka, M., Aselcioglu, I., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010725 · Cited by 45
Self-citationSmith, G. S., Protas, H., Kuwabara, H., Savonenko, A., Nassery, N., Gould, N. F., Kraut, M., Avramopoulos, D., Holt, D., Dannals, R. F., et al. (2023) · NeuroImage: Clinical · doi:10.1016/j.nicl.2023.103322 · Cited by 22
Qin, M., Wu, J., Zhou, Q., Liang, Z., & Su, Y. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.09.039 · Cited by 12
Metadata
- Authors
- Cirrito, J. R., Wallace, C. E., Yan, P., Davis, T. A., Gardiner, W. D., Doherty, B. M., King, D., Yuede, C. M., Lee, J.-M., & Sheline, Y. I.
- Venue
- Neurology
- Published
- 2020-11-10
- Volume
- 95
- Issue
- 19
- Pages
- e2666-e2674
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3084765062
- Cited by
- 63
- References
- 23
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. https://app.cochat.ai/papers/10.1212/wnl.0000000000010733
- The paper
- Cirrito, J. R., Wallace, C. E., Yan, P., Davis, T. A., Gardiner, W. D., Doherty, B. M., King, D., Yuede, C. M., Lee, J.-M., & Sheline, Y. I. (2020). Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. Neurology. https://doi.org/10.1212/wnl.0000000000010733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.